Altamira Therapeutics is dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus, and restore balance. Altamira Therapeutics is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo. They have additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the “BiFAR” technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for the occurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quark's approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

The House Ear Institute (HEI) is a non-profit 501(c)(3) organization, based in Los Angeles, California, and dedicated to advancing hearing science through research, education, and global hearing health to improve quality of life. Established in 1946 by Howard P. House, as the Los Angeles Foundation of Otology, and later renamed for its founder, the House Ear Institute has been engaged in the scientific exploration of the auditory system from the ear canal to the cortex of the brain for over 70 years.

House Ear Institute is a private nonprofit foundation that focus on global health otology projects.

Shanghai Bode Gene Development Co., Ltd., established on 1998-03-22, Business scope includes bioengineering,Technology transfer in the field of genetic engineering expertise,technology development,technical consulting,Technical services and manufacture of related reagents and equipment,Sales;Bioengineering and Genetic Engineering Products,electronics,Chemical Products(In addition to dangerous goods)import and export business. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

ETRI is the largest government funded research institute in Korea, which strives to advance science by means of formulating innovative ideas; developing new techniques; and training professional individuals in the area of information telecommunications to ultimately enhance social and economical aspects of the modern society.

Beida Wankun (Beijing) Technology Development Co., Ltd., established on 2007-04-17, Business scope includes technology development,technology transfer,technical consulting,Technical Services;selling computers,Software and Auxiliary Equipment.(Except for projects without administrative permission)(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

FANCL Corp. engages in the manufacture and sale of cosmetics and nutritional supplements. It operates through the following segments: Cosmetics, Nutritional Supplements, and Others. The Cosmetics segment deals with manufacture and sale of cosmetics and provides original equipment manufacturer products. The Nutritional Supplements segment handles manufacture and sale of food supplements. The Others segment includes online sales of undergarments, health equipment, and lifestyle products. It also offers germinated brown rice, kale juice, and esthetic business. The company was founded by Kenji Ikemori in April 1980 and is headquartered in Yokohama, Japan.

Seasun Biomaterials, Inc. provides NGS services and real time PCR based diagnostic products. Its products and services include diagnostics, therapeutics, genome sequencing, transcriptome, and metagenome. The company was founded by Hee Gyeong Park on May 20, 2012 and is headquartered in Daejeon, South Korea.

The First Hospital of Jilin University, part of Jilin University, is a company headquartered in Changchun, China. The firm owns and operates hospital.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. Qilu focuses on the development, manufacturing and marketing of generic drugs and active pharmaceutical ingredients(APIs) in therapeutic areas including but not limited to Oncology, Cerebrovascular & Cardiovascular, Anti-infections, Psychological & Neurological Systems, Respiratory System, and Ophthalmological Diseases. Qilu has more than 15,000 employees, 70% of whom have a college degree or above. Qilu Pharmaceutical consistently focuses on revolutionary development strategies guided by market demand and product innovation. Qilu has established extensive cooperation with domestic and international partners on multiple R&D projects. Devoted to the cultivation of talent, Qilu has invested in a highly qualified R&D team and efficient R&D capabilities. The 200+ new drug products successfully developed by Qilu constitutes as a large part of future production and sales for Qilu Pharmaceutical and partners. A number of technological achievements have garnered national and provincial scientific and technological progress awards for Qilu.

Toyama Chemical Co., Ltd. develops and supplies pharmaceutical products. It engages in information collection, clinical development of pharmaceuticals and distribution of healthcare products. The company was founded on November 15, 1936 and is headquartered in Tokyo, Japan.

Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes, and from these, three product candidates have been advanced into development.